Evidence map›Paper›PMID 40094002›Full record

ArticleFrontiers in oncology2025

Case Report and review of the literature: esophageal pleomorphic rhabdomyosarcoma.

Matteo Pittacolo, Arianna Vittori, Lucia Moletta, Gianpietro Zanchettin, Elisa Sefora Pierobon, Giovanni Capovilla, Renato Salvador, Mauro Michelotto, Michele Valmasoni

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matteo PittacoloDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.
Arianna VittoriDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.
Lucia MolettaDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.
Gianpietro Zanchettin1st Surgical Clinic, University Hospital of Padua, Padova, Italy.
Elisa Sefora Pierobon1st Surgical Clinic, University Hospital of Padua, Padova, Italy.
Giovanni Capovilla1st Surgical Clinic, University Hospital of Padua, Padova, Italy.
Renato SalvadorDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.
Mauro MichelottoSurgical Pathology Unit, University Hospital of Padua, Padova, Italy.
Michele ValmasoniDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Esophageal rhabdomyosarcoma is an exceedingly rare malignant tumor, with only three cases comprehensively documented in the literature since 1995. Due to its rarity, there is limited information on the epidemiology and diagnosis of this disease, and no standardized treatment protocols have been established. As a result, both the recognition and management of esophageal rhabdomyosarcoma pose significant challenges. The present case report provides valuable insight into the clinical approach to this rare tumor, highlighting the need for further research and investigation to develop more effective diagnostic tools and therapeutic strategies. Case Presentation: We described the case of a 77-year-old male who presented with dyspepsia and anemia, leading to the discovery of an esophageal lesion. At the index endoscopy, histological findings were consistent with esophageal adenocarcinoma. Consequently, the patient was treated with neoadjuvant chemotherapy and Ivor Lewis esophagectomy. Interestingly, on pathological examination the lesion was identified as a pleomorphic rhabdomyosarcoma of the esophagus. Postoperatively, the patient received adjuvant chemotherapy. Subsequently, a subcutaneous metastatic lesion on his right shoulder was treated with a combination of radiotherapy and surgical excision. The patients died twenty-six months after the initial diagnosis. Conclusions: Our case represents one of the few reported instances of esophageal rhabdomyosarcoma, a highly rare and aggressive malignancy, and provides valuable insights into the challenges of diagnosing and managing this disease. Moreover, this is one of the first cases of esophageal rhabdomyosarcoma followed up for more than 24 months. However, given the paucity of data on esophageal rhabdomyosarcoma, there remains a significant unmet need for more comprehensive studies to establish standardized diagnostic and therapeutic protocols.

Indexed as

case reportesophageal rhabdomyosarcomaesophagectomymanagementmetastasesprognosis

Identifiers

PMID40094002
PMCPMC11906311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.